Antoine G Van Der Heijden

List of Publications by Year
in descending order

49 papers	5,219 citations	257450 24 h-index	206112 48 g-index
51 all docs	51 docs citations	51 times ranked	5411 citing authors

#	Article	IF	Citations
1	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Urology, 2017, 71, 462-475.	1.9	1,241
2	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology, 2021, 79, 82-104.	1.9	1,152
3	EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. European Urology, 2014, 65, 778-792.	1.9	868
4	European Association of Urology (EAU) Prognostic Factor Risk Groups for Nonâ€“muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. European Urology, 2021, 79, 480-488.	1.9	198
5	Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-GuÃ©rin for Adjuvant Treatment of Patients with Intermediate- and High-risk Nonâ€“Muscle-invasive Bladder Cancer. European Urology, 2016, 69, 1046-1052.	1.9	176
6	The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review. European Urology, 2014, 66, 1065-1077.	1.9	164
7	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. European Urology, 2022, 81, 95-103.	1.9	158
8	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€”An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
9	Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nature Reviews Urology, 2020, 17, 513-525.	3.8	94
10	EFFECT OF HYPERTHERMIA ON THE CYTOTOXICITY OF 4 CHEMOTHERAPEUTIC AGENTS CURRENTLY USED FOR THE TREATMENT OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER: AN IN VITRO STUDY. Journal of Urology, 2005, 173, 1375-1380.	0.4	92
11	Treatment of High-grade Nonâ€“muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial â€œNIMBUSâ€. European Urology, 2020, 78, 690-698.	1.9	76
12	Comparison of Hexaminolevulinate Based Flexible and Rigid Fluorescence Cystoscopy with Rigid White Light Cystoscopy in Bladder Cancer: Results of a Prospective Phase II Study. European Urology, 2005, 47, 319-322.	1.9	75
13	A five-gene expression signature to predict progression in T1G3 bladder cancer. European Journal of Cancer, 2016, 64, 127-136.	2.8	67
14	Systematic review of the oncological and functional outcomes of pelvic organâ€preserving radical cystectomy (<scp>RC</scp>) compared with standard <scp>RC</scp> in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU International, 2017, 120, 12-24.	2.5	63
15	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. European Urology Oncology, 2020, 3, 131-144.	5.4	61
16	Combined Chemohyperthermia: 10-Year Single Center Experience in 160 Patients with Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2014, 192, 708-713.	0.4	56
17	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Nonâ€“muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Nonâ€“muscle-invasive Bladder Cancer Guidelines Panel Study. European Urology Oncology, 2021, 4, 182-191.	5.4	54
18	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Human Molecular Genetics, 2014, 23, 5545-5557.	2.9	46

#	Article	IF	Citations
19	Oncological and functional outcomes of sexual functionâ€“preserving cystectomy compared with standard radical cystectomy in men: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 539.e17-539.e29.	1.6	43
20	The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 166.e1-166.e6.	1.6	39
21	Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. European Journal of Cancer, 2016, 54, 131-138.	2.8	32
22	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World Journal of Urology, 2019, 37, 51-60.	2.2	31
23	Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer. International Journal of Hyperthermia, 2016, 32, 434-445.	2.5	29
24	Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder. Cancers, 2020, 12, 2692.	3.7	29
25	European Association of Urology Guidelines on Primary Urethral Carcinomaâ€”2020 Update. European Urology Oncology, 2020, 3, 424-432.	5.4	28
26	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 440-448.	1.6	27
27	The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. World Journal of Urology, 2014, 32, 651-9.	2.2	23
28	Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2015, 13, 204-209.e2.	1.9	17
29	Radical Cystectomy in a Dutch University Hospital: Long-Term Outcomes and Prognostic Factors in a Homogeneous Surgery-Only Series. Clinical Genitourinary Cancer, 2014, 12, 190-195.	1.9	14
30	Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. International Journal of Hyperthermia, 2018, 34, 988-993.	2.5	14
31	Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. Cancers, 2021, 13, 377.	3.7	13
32	The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder. International Journal of Cancer, 2021, 148, 981-987.	5.1	12
33	The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis. World Journal of Urology, 2007, 25, 303-308.	2.2	10
34	Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World Journal of Urology, 2015, 33, 1411-1417.	2.2	10
35	Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study. Cancer Treatment and Research Communications, 2020, 25, 100266.	1.7	10
36	Survival after radical cystectomy: Progressive versus De novo muscle invasive bladder cancer. Cancer Treatment and Research Communications, 2020, 25, 100264.	1.7	8

#	Article	IF	Citations
37	Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication. Scientific Reports, 2021, 11, 6132.	3.3	7
38	Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnostics: The Replacement for Surgery?. European Urology Oncology, 2020, 3, 316-317.	5.4	6
39	Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study. European Urology Focus, 2022, 8, 995-1002.	3.1	6
40	Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. Translational Research, 2019, 208, 73-84.	5.0	5
41	Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the â€˜trials within cohortsâ€™ study ProBCI. BMJ Open, 2021, 11, e047256.	1.9	5
42	Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer. Frontiers in Immunology, 2021, 12, 802877.	4.8	5
43	The role of methylation in urological tumours. Archivos Espanoles De Urologia, 2013, 66, 432-9.	0.2	4
44	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Nonâ€“muscle-invasive Bladder Cancer Spectrum. European Urology Focus, 2022, , .	3.1	4
45	Orthotopic urinary diversions after radical cystectomy for bladder cancer: lessons learned last decade. Current Opinion in Urology, 2021, 31, 580-585.	1.8	3
46	Reply to Francesco Montorsi, Marco Bandini, Alberto Briganti, et al. Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. Eur Urol 2020;78:489â€“91. European Urology, 2020, 78, 492-493.	1.9	2
47	Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography. Journal of Personalized Medicine, 2022, 12, 726.	2.5	2
48	Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome. Cancer Immunology, Immunotherapy, 0, , .	4.2	1
49	Reply to letter commenting on: A five-gene expression signature to predict progression in T1G3 bladder cancer. European Journal of Cancer, 2016, 68, 198.	2.8	0